Characteristics of patients with neuropathic pain syndromes screened by the painDETECT questionnaire and diagnosed by physician exam
Brief Pain Inventory
DOI:
10.2147/jpr.s160513
Publication Date:
2019-01-06T22:47:17Z
AUTHORS (13)
ABSTRACT
The aim of this study was to identify the clinical characteristics, treatment usage, and health outcomes US adults diagnosed with neuropathic pain (NeP) by experienced physicians.Adults scores exceeding threshold for probable NeP (painDETECT ≥19) a qualified physician completed questionnaire that included comorbid conditions, symptoms experiences, medication use, status (3-level EuroQol 5 Dimensions (EQ-5D-3L]: utilities index visual analog scale), severity interference functioning (Brief Pain Inventory), work activity impairment (Work Productivity Activity Impairment questionnaire). Descriptive analyses were performed each subtype.Participants (n=295) predominantly female (64.4%), middle-aged (53.9%), white (51.5%). Chronic low back most frequently major syndrome (n=166), followed diabetic peripheral neuropathy (n=58), post-trauma (n=47), post-surgical (n=28), central (n=23). An additional 45 participants diagnosed, but did not meet criteria aforementioned subtypes. Participants could be multiple Across subtype, patients reported high rates disease, including arthritis (range: 39.1%-64.3%) blood pressure 26.1%-69.0%), as well symptomology numbness 68.1%-91.4%) changes in muscular strength 24.1%-65.2%). majority 77.8%-95.7%) arthritis/joint 68.1%-78.6%). commonly types non-steroidal anti-inflammatory drugs 43.1%-70.2%), weak opioids 22.2%-39.3%), strong 8.7%-28.6%). All six groups generally similar levels dysfunction on all self-report measures. notable finding EuroQol-5D-3L lower than norms clinically important amount.These exploratory findings indicate across different etiologies are medically complex experience impaired function domains.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (12)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....